NewLink Genetics Corporation (NASDAQ:NLNK) opened at $18.7100 in last trading session while in today’s session it was seen trading around $19.2339 on a volume of 551643 shares. So far in the session, the stock’s high was $19.2400 and low $18.2060. The market capitalisation of NewLink Genetics Corporation, a NGM listed firm, stands at $553.71M. An average of 640224 shares traded on a day-to-day basis since the last three months. NewLink Genetics Corporation 52 week range is $15.6800 – 58.7300 while the short ratio stands at 8.5000.
The technical analysis divulges that the stock is +0.4874% away from its 50-Day MA of $19.1406. By exploring further, it illustrates that the current price of the firm’ stock is $-39.4961 and $3.5539 off from its 52-week high and one-year low of $58.7300 and $15.6800, respectively.
In addition to the earnings, the market experts have released the future prices. The consensus one-year price target is placed at $47.8300. The company’s EPS in past year is $-1.4130. As per the latest update, the EPS estimate for the near-term quarter is set at $-0.8700. Analysts have EPS target of $-3.4000 for the current year and $-3.5900 for next year.
The stock’s valuation metric, price to earnings ratio stands at N/A. P/E ratio is one of the extensively applied and popular stock valuation tools. In simple words, it can be explained as a ratio of a firm’s current share price relative to its annual EPS. It divulges the sentiment of the stockholders.
If the ratio is high, it signifies investors are confident and expect higher earnings growth in the upcoming period, and vice-versa. Price to earnings ratio implies how cheap or expensive a firm’s stock is. If P.E ratio of any stock is 10, it tells that stakeholders are willing to pay ten times of a firm’s earning to buy that stock.
Brokerages projected NewLink Genetics Corporation Price to Current fiscal EPS at N/A and for next year at N/A. The firm has a dividend yield of N/A%. Following the book value of $6.8000, the stock’s price to book value is 2.7382. The EBITDA is noted at $-32.17M while the price-to-sales ratio stands at 7.8252.